06:00 PM EDT, 07/21/2025 (MT Newswires) -- AstraZeneca ( AZN ) said late Monday it plans to invest $50 billion in the US by 2030 to expand medicines manufacturing and research and development.

The investment will facilitate the construction of a new manufacturing facility in the Commonwealth of Virginia focused on drug substances for weight management and metabolic disease treatments.

The funding will also support expansions across Maryland, Massachusetts, Indiana, California, and Texas, including cell therapy manufacturing, continuous manufacturing, and clinical trial supply sites.

AstraZeneca ( AZN ) said the investment supports its goal of reaching $80 billion in revenue by 2030, with half expected to come from the US.